Еvaluation the functional reserve of the kidneys in patients with chronic heart failure who have had the COVID-19 infection

   THE AIM: to evaluate the functional reserve of the kidneys (FRK), and the effectiveness of empagliflozin (EMPA), a selective reversible inhibitor of sodium-glucose cotransporter type 2 (SGLT 2), in patients with chronic heart failure who have had COVID-19 infection.

   PATIENTS AND METHODS: To assess the state of renal function in patients with coronary heart disease (CHF), the most accessible and convenient method for determining FRK using 0.45 % saline was chosen. The study involved 110 patients with CHF developed as a result of coronary artery disease and hypertension. The first group consisted of 40 patients
with CHF who have had COVID-19 infection (16 (40 %) men and 24 (60 %) women, mean age 63.2 ± 1.2 years). They received EMPA in addition to standard therapy. The second group consisted of 40 patients with CHF who have also had COVID-19 (24 (60 %) men and 16 (40 %) women, mean age 64.1 ± 1.2 years). They received only standard therapy (ACE inhibitors or ARB,
beta-blockers, AMCR). The control group consisted of 30 CHF patients who haven’t had COVID-19 infection (16 (53.33 %) men and 14 (46.67 %) women, mean age 61.8 ± 1.2 years). They received only standard therapy.

   RESULTS. In patients of the first group (standard treatment+ EMPA) the FRK was 2.9 ± 0.2 % before and 8.1 ± 0.2 % after the treatment, which indicates a significant increase (p<0.001). The creatinine level before the treatment and exercise was 147.7±2.7 μmol/l, and after the exercise, it decreased to 144.7±2.5 μmol/l. After the standard therapy, a decrease in its index by 102.5±1.4 μmol/l and 99.7 ± 1.3 μmol/l, respectively, was established. The glomerular filtration rate before treatment and exercise was 56.8 ± 1.5 ml/min, and after exercise, it increased to 54.3 ± 1.6 ml/min. After the treatment, these values were 60.3 ± 2.01 ml/min and 62.7±2.08 ml/min, respectively. In patients of the second group (standard treatment), FRK was 4.4 ± 0.1 % before and 3.0 ± 0.2 % after treatment.

   CONCLUSION: Thus, in patients of the first group, who received EMPA along with standard CHF treatment, an increase in FRK by 2.8 times was found (p < 0.01). In the group of patients with CHF who did not receive an inhibitor of sodium-glucose transporter type 2 EMPA in combination with standard therapy, a decrease in FRK by 1.3 times was found (p > 0.05). While in the control group, FRK increased by 1.1 times (p > 0.05). Thus, the results show that in the first group, the FRK index was 2.9 %, which indicates the absence of a reserve, while after complex therapy in combination with EMPA, this increased to 8.1 %, which indicates the presence of a reserve. However, in the second group, the decrease in these indicators from 4.4 % to 3.3 %, respectively, suggests the absence of FRK. In the control group, this figure increased from 6.7 % before treatment to 7.1 % after.
This indicates a decrease in FRK in this group of patients. Thus, the decrease in the FRK in patients of the first group compared with the control indicates an adverse effect of COVID-19 on the kidneys. It is confirmed in numerous studies, which makes us think about its long-term effect not only in the acute period of infection but also after the clinical convalescence.

1. Гриневич В. Б. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции. Национальный консенсус 2020 / В. Б. Гриневич [и др.] // Кардиоваскулярная терапия и профилактика. – 2020. –19 (4): 2630. https://doi.org/10.15829/1728-8800-2020-2630 / Grinevich V. B., Gubonina I. V., Doshchitsin V. L. et al. Features of management of comorbid patients during the pandemic of a new coronavirus infection. National Consensus 2020. Cardiovascular Therapy and Prevention 2020; 19 (4): 2630 (In Russ.). https://doi.org/10.15829/1728-8800-2020-2630

2. Денисенко И. Л. Определение почечного функционального резерва / И. Л. Денисенко, Л. Н. Акимова, Т. О. Абисова // Клин. Лаб. Диагн. – 2000. – 1: 17–18 / Denisenko I. L, Akimova L. N., Abisova T. O. Determination of the renal functional reserve. Klin Lab Diagn 2000; 1: 17–18

3. Шейман Дж. А.. Патофизиология почки / Джеймс А. Шейман. – М., 1997. – 224. / James A. Sheiman. Pathophysiology of the kidney. M., 1997, 224

4. Есаян А. М. Влияние белковой нагрузки на функциональное состояние почек у больных хроническим гломерулонефритом / А. М. Есаян [и др.] // Тер. Арх. – 2002. – 6: 19–24. / Yesayan A. M., Kucher A. G., Kayukov I. G. et al. Influence of protein load on the functional state of the kidneys in patients with chronic glomerulonephritis. Ter Arch 2002; 6: 19–24

5. Кутырина И. М. Гиперфильтрация как фактор прогрессирования хронических заболеваний почек / И. М. Кутырина [и др.] // Тер. Арх. – 1992. – 6: 10–15 / Kutyrina I. M., Rogov V. A., Shestakova M. V. Hyperfiltration as a factor in the progression of chronic kidney disease. Ter Arch 1992; 6: 10–15

6. Нестеров В. С. ХСН: Современные проблемы и пути их решения / В. С. Нестеров, И. А. Урванцева, А. С. Воробьев. – 2018. – Lvrach.ru / Nesterov V. S., Urvantseva I. A., Vorobyov A. S.. CHF: Modern problems and ways to solve them. 2018. Lvrach.ru

7. Рогов В. А. Функциональный резерв почек при нефротическом синдроме / В. А. Рогов [и др.] // Тер. Арх. – 1990. – 6: 55–58 / Rogov V. A., Kutyrina I. M., Tareeva I. E. and other. Functional reserve of the kidneys in nephrotic syndrome. Ter Arch 1990; 6: 55–58

8. Тареева И. Е. Нефрология: руководство для врачей / И. Е. Тареевой. – М.: Медицина, 2000. / Tareeva I. E. Nephrology: a guide for doctors. Medicine, M., 2000

9. Харламова У. В. Состояние эндотелиальной функции и системы гемостаза и больных на гемодиализе / У. В. Харламова, О. Е. Ильичева // Нефрология. – 2010. – 14 (4): 48–52. / Kharlamova U. V., Ilyicheva O. E. State of endothelial function and hemostasis system and patients on hemodialysis. Nephrology 2010; 14 (4): 48–52

10. Шамхалова М. Ш. COVID-19 и почки / М. Ш. Шамхалова, Н. Г. Мокрышева, М. В. Шестакова // Сахарный диабет. – 2020. – 23 (3): 235–241. https://doi.org/10.14341/DM12506 / Shamkhalova M. Sh., Mokrysheva N. G., Shestakova M. V. COVID-19 and kidneys. Diabetes 2020; 23 (3): 235–241. https://doi.org/10.14341/DM12506

11. Яркова Н. А. Нефрин – ранний маркер повреждения почек при сахарном диабете 2-го типа/ Н. А. Яркова // Медицинский альманах. – 2017. – 47 (2): 101–103 / Yarkova N. A. Nephrin is an early marker of kidney damage in type 2 diabetes mellitus. Medical almanac 2017; 47 (2): 29–33

12. Addis T., Barrett E., Poo L. J., Ureen H. J., Lippman R. W. The relation between protein consumption and diurnal variations of the endogenous creatinine clearance in normal individuals. J Clin Invest 1951 Feb; 30 (2): 206–209. doi: 10.1172/JCI102433

13. Bosch J. P., Saccaggi A., Lauer A., Ronco C., Belledonne M., Glabman S. Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. Am J Med 1983 Dec; 75 (6): 943–950. doi: 10.1016/0002-9343(83)90873-2

14. Bosch J. P., Lew S., Glabman S., Lauer A. Renal hemodynamic changes in humans. Response to protein loading in normal and diseased kidneys. Am J Med 1986 Nov; 81 (5): 809–815. doi: 10.1016/0002-9343(86)90350-5

15. Brenner B. M., Meyer T. W., Hostetter T. H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982 Sep 9; 307 (11): 652–659. doi: 10.1056/NEJM198209093071104

16. Gadaev A., Turakulov R. I., Qurbonov А., Sabirov M. A. Assessment of erythropoietin levels and correlation with cytokines in patients with chronic heart failure. International Journal of Pharmaceutical Research 2021; 713–720

17. Henry B. M., Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020; 52 (6): 1193–1194. doi: 10.1007/s11255-020-02451-9

18. Schück O., Teplan V., Jabor A., Stollova M., Skibova J. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels. Nephron Clin Pract 2003; 93 (4): 146–151. doi: 10.1159/000070234

19. Shrier Robert W. Diseases of the kidney and urinary tract. Lippincott Williams & Wilkins 2001; 1

20. Staels B. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. Am J Med 2017 Jun; 130 (6S): S30–S39. doi: 10.1016/j.amjmed.2017.04.009

21. Turakulov R. I., Sayfullayev M. B. Gadayeva NA. Features of differential diagnosis of anemia of chronic disease and iron deficiency anemia Comorbidities in chronic heart failure. Challenges in science of nowadays 26-28. 11. 2020 Washington, USA Р. 1095-1100